IBRNvsXPHETF Comparison
VS
iShares Neuroscience and Healthcare ETF (IBRN) belongs to the Healthcare Technology segment. State Street SPDR S&P Pharmaceuticals ETF (XPH) is part of the US Health Care segment. IBRN's top 2 sector exposures are Healthcare and Non-Corporate. In contrast, XPH's top sector exposures are Healthcare. IBRN is more expensive with a Total Expense Ratio (TER) of 0.47%, versus 0.35% for XPH. IBRN is up 21.65% year-to-date (YTD) with +$2M in YTD flows. XPH performs better with 26.77% YTD performance, and +$299M in YTD flows. Run a side-by-side ETF comparison of IBRN and XPH below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
Find out how industry players manage ETF portfolios. Discover our library of Model portfolios
IBRN vs XPH performance and flow charts
Performance
Cumulative Flows
Historic performance and flows
Data as of 09/03/2026
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | IBRN XPH | +7.31%+4.06% | +14.35%+26.13% | +21.65%+26.77% | +55.92%+50.22% | +75.03%+69.84% | n/a+54.67% |
| Flows | IBRN XPH | +$2M+$110M | +$2M+$186M | +$2M+$299M | +$2M+$307M | +$759K+$246M | -+$268M |
Volatility and drawdown
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | IBRN XPH | +24.59%+23.09% | +25.79%+22.45% | +25.17%+20.48% | n/a+20.85% |
| Max drawdown | IBRN XPH | -9.28%-5.29% | -9.28%-11.78% | -34.98%-23.45% | n/a-30.87% |
| Max drawdown duration | IBRN XPH | 40d15d | 40d50d | 338d322d | n/a1452d |
Trading data
IBRN | XPH | |
Last sale 9/3/2026 at 1:30 PM | $39.37 | $71.02 |
| Previous close 09/03/2026 | $39.46 | $71.03 |
| Consolidated volume 09/03/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Replication quality
Data as of August 31, 2026
1-year trailing difference
Create an account to view replication metrics
Join for free
IBRN | XPH | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
Advertisement
Main metrics
Last update 9/3/2026 at 1:30 PM
Live
Closed
IBRN | XPH | |
|---|---|---|
| Last price | $39.37 | $71.02 |
| 1D performance | -0.21% | -0.01% |
| AuM | $7.86 M | $620.88 M |
| E/R | 0.47% | 0.35% |
Characteristics
IBRN | XPH | |
|---|---|---|
| Management strategy | Passive | Passive |
| Provider | iShares | State Street Investment Management |
| Benchmark | NYSE FactSet Global Neuro Biopharma and MedTech Index | S&P Pharmaceuticals Select Industry Index |
| N° of holdings | 69 | 63 |
| Asset class | Equities | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | August 24, 2022 | June 19, 2006 |
| ESG | No | No |
Advertisement
Exposure
Countries
IBRN
USA
73.57%
Other
26.43%
XPH
USA
89.67%
Other
10.33%
Sectors
IBRN
Healthcare
99.87%
Other
0.13%
XPH
Healthcare
94.18%
Other
5.82%
Advertisement
Diversification
IBRN
Total weight of top 15 holdings out of 15
64.26%
XPH
Total weight of top 15 holdings out of 15
32.65%
Top 15 holdings
Data as of July 31, 2026
IBRN
Dianthus Therapeutics, Inc.
5.45%
Xenon Pharmaceuticals, Inc.
4.83%
Praxis Precision Medicines, Inc.
4.72%
ACADIA Pharmaceuticals, Inc.
4.66%
Arrowhead Pharmaceuticals, Inc.
4.65%
Alkermes Plc
4.55%
Neurocrine Biosciences, Inc.
4.41%
Scholar Rock Holding Corp.
4.31%
PTC Therapeutics, Inc.
4.15%
Biogen, Inc.
4.15%
Axsome Therapeutics, Inc.
3.93%
argenx SE
3.82%
Denali Therapeutics, Inc.
3.76%
Dyne Therapeutics, Inc.
3.53%
Edgewise Therapeutics, Inc.
3.35%
XPH
Crinetics Pharmaceuticals, Inc.
3.69%
MBX Biosciences, Inc.
3.22%
Amylyx Pharmaceuticals, Inc.
2.29%
Enliven Therapeutics, Inc.
2.24%
Corcept Therapeutics, Inc.
2.22%
Alumis, Inc.
2.13%
Nuvation Bio, Inc.
2.09%
Trevi Therapeutics, Inc.
2.06%
Liquidia Corp.
1.95%
Nektar Therapeutics
1.89%
Amneal Pharmaceuticals, Inc.
1.81%
Bristol Myers Squibb Co.
1.78%
Edgewise Therapeutics, Inc.
1.77%
Omeros Corp.
1.76%
Ligand Pharmaceuticals, Inc.
1.75%
Frequently asked questions about IBRN and XPH
How have the IBRN and XPH ETFs performed in 2026?
As of September 3, 2026, IBRN is up 21.65% year-to-date (YTD), while XPH has returned 26.77%. That puts XPH better performer ahead so far this year.
Which ETF is attracting more investor money: IBRN or XPH?
Year-to-date, the IBRN ETF saw +$2M in flows, compared to +$299M for XPH.
Which ETF is more volatile: IBRN or XPH?
Over the past year, IBRN had a volatility of 25.79%, while XPH experienced 22.45%.
Which ETF is bigger: IBRN or XPH?
As of September 3, 2026, IBRN holds $7.86 M in assets under management (AUM), while XPH manages $620.88 M.
What sectors do the IBRN and XPH ETFs invest in?
IBRN leans toward sectors like Healthcare. Meanwhile, XPH focuses on Healthcare.
What are the top holdings of the IBRN ETF and XPH ETF?
IBRN top holdings include Dianthus Therapeutics, Inc., Xenon Pharmaceuticals, Inc. and Praxis Precision Medicines, Inc.. XPH holds in its top three: Crinetics Pharmaceuticals, Inc., MBX Biosciences, Inc. and Amylyx Pharmaceuticals, Inc..
Which ETF is more diversified: IBRN or XPH?
IBRN holds 69 securities with 64.26% of its assets in the top 15. XPH has 63 securities and a top 15 weight of 32.65%.
Advertisement
Latest news about IBRN & XPH
Donald Trump’s Executive Orders: ETF Bulls and Bears
January 24, 2025
XPH
Analyzing the Potential ETF Winners & Losers from The Weight-Loss Drug Craze
November 20, 2023
XPH
Advertisement
Advertisement
